CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023 16:15 ET
|
CytomX Therapeutics Inc.
- CX-904 (EGFRxCD3) initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b)...
CytomX Therapeutics to Report Second Quarter 2023 Financial Results on August 8, 2023
August 01, 2023 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Announces New Employment Inducement Grants
July 20, 2023 09:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
CytomX Therapeutics Appoints Yu-Waye (Wayne) Chu, M.D., as Chief Medical Officer
July 17, 2023 08:00 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the...
CytomX Therapeutics Announces $30 Million Private Placement from BVF Partners L.P.
June 30, 2023 08:00 ET
|
CytomX Therapeutics Inc.
- Financing is expected to extend cash runway into the 2nd half of 2025 based on current operating plans, enabling the Company to reach multiple clinical milestones - - $30 million initial investment...
CytomX Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023 16:05 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:15 ET
|
CytomX Therapeutics Inc.
- Continued progress in Phase 1 dose escalation for CX-904 (EGFRxCD3) - - IND enabling activities on track for filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon...
CytomX Therapeutics to Report First Quarter 2023 Financial Results on May 9, 2023
May 01, 2023 16:01 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 25, 2023 16:05 ET
|
CytomX Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced that...
CytomX Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
March 27, 2023 16:15 ET
|
CytomX Therapeutics Inc.
- Internal focus on next generation therapeutic pipeline including ongoing Phase 1 for CX-904 (EGFRxCD3) and anticipated IND filings for CX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b)...